The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin ...

This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...

Commercial launch in Switzerland anticipated in H2 2026Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces ...

No player's role was impacted more by the return of Gleyber Torres than Colt Keith. Yet, you'd never know it by his upbeat reaction to the news.

Vanderpump Rules alum Lala Kent detailed her rare reaction to a bug bite which resulted in oozing painful and itchy boils all ...

Struggling with blind pimples? Learn how to treat cystic acne fast with dermatologist-approved products and proven at-home ...

While hiccups are usually harmless and short-lived, they can, in rare circumstances, become medically significant ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Every winter, Austin gets walloped by cedar fever: runny noses, scratchy throats, watering eyes, and canceled plans as ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, ...